Lv1
84 积分 2023-08-09 加入
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study
19天前
已完结
New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024
21天前
已完结
Nonalcoholic Steatohepatitis
22天前
已完结
Fibroblast growth factor 21: A “rheostat” for metabolic regulation?
22天前
已完结
FGF21 reloaded: challenges of a rapidly growing field
22天前
已完结
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
27天前
已完结
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
1个月前
已完结
A structural basis for amylin receptor phenotype
1个月前
已完结
THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology
1个月前
已完结
Structural insight into selectivity of amylin and calcitonin receptor agonists
1个月前
已完结
皖公网安备34019202002308
